argenx SE (NASDAQ:ARGX) Q3 2021 Results Conference Call October 28, 2021 8:30 AM ET Company Participants Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Akash Tewari - Jefferies James Gordon - JP Morgan Danielle Brill - Raymond James Yatin Suneja - Guggenheim Joon Lee - Truist Tazeen Ahmad - Bank of America Rosie Turner - Barclays Jason Butler - JMP Securities Joel Beatty - Robert W. Baird Yanan Zhu - Wells Fargo Douglas Tsao - H. C. Wainwright Charles Pitman - Re ...

argenx SE (NASDAQ:ARGX) Q2 2021 Earnings Conference Call July 29, 2021 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Keith Woods - Chief Operating Officer Conference Call Participants Joon Lee - SunTrust Tazeen Ahmad - Bank of America Max Skor - Morgan Stanley Brendan Smith - Cowen Andrew Galler - Wolfe Research Yanan Zhu - Wells Fargo Thomas Vranken - KBC Securities Graig Suvannavejh - ...

argenx SE (NASDAQ:ARGX) Q1 2021 Earnings Conference Call May 14, 2021 8:30 AM ET Company Participants Beth DelGiacco - Vice President of Corporate Communications & Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Eric Castaldi - Chief Financial Officer Keith Woods - Chief Operating Officer Conference Call Participants Derek Archila - Stifel Amy Li - Wolfe Research Tazeen Ahmad - Bank of America Joon Lee - Truist Securities Danielle Brill - Raymond James Yaron Werber - Cowen & Company Jason ...

Business Overview - argenx aims to reach patients through immunology innovation, focusing on late-stage pipeline development and commercial franchises[3] - The company has a strong balance sheet with a pro-forma cash position of approximately $3.1 billion[3] - Efgartigimod has achieved proof-of-concept in 4 out of 4 indications, including 2 out of 2 in the neuromuscular franchise[13] Efgartigimod Development - A bridging study (n=50) is underway to support registration of subcutaneous efgartigimod, demonstrating non-inferiority of pharmacodynamic effect of 1000 mg SC efgartigimod to 10mg/kg IV efgartigimod[31] - In Myasthenia Gravis (MG), a person with MG on a good day operates at 70%, while on bad days, they can get 10% out of their battery[22] - Approximately half (1/2) of MG patients have been diagnosed with depression or anxiety in addition to gMG[22] Pipeline and Programs - Cusatuzumab is being developed for newly diagnosed elderly AML patients who are unfit for intensive chemotherapy[59] - In the Phase 2 CULMINATE trial of Cusatuzumab + Azacitidine 20 mg/kg, the 30-day mortality rate was 9.6% (5/52)[67] - ARGX-117, targeting the innate immune system, is in Phase 1 with healthy volunteer data expected mid-2021[55] Regulatory and Global Expansion - The BLA for IV efgartigimod for the treatment of gMG has been accepted for review by the FDA, with a PDUFA date of December 17, 2021[47]

argenx SE (NASDAQ:ARGX) Q4 2020 Results Conference Call March 4, 2021 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Eric Castaldi - Chief Financial Officer Keith Woods - Chief Operating Officer Conference Call Participants Brendan Smith - Cowen David Nierengarten - Wedbush Max Skor - Morgan Stanley Tazeen Ahmad - Bank of America Danielle Brill - Raymond James Graig Suvannavejh - Goldman Sachs Am ...